GNI GNI GROUP LTD.

Contact Us
About Us
  • About Us TOP
  • Message
  • Business Model
  • Main Products
  • Management Policy
  • Company Overview
  • Board of Directors
  • Main Group Structure
  • Office
  • Corporate governance
R&D
  • R&D TOP
  • Pipeline
  • Discovery Research
  • Research publications
Investor Relations
  • Investor Relations TOP
  • IR News
  • Information
  • IR Materials
  • IR Calendar
  • IR Email Subscription
  • Electronic Public Notices
Sustainability/ESG
  • Sustainability/ESG TOP
  • Sustainability Initiatives
  • ESG Data
Contact Us
Site Map
Privacy Policy
Terms of Use
ソーシャルメディアポリシー

Information

トップページInformation
2011/09/22
China SFDA Approves F647/Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis
2011/09/15
World Orphan Drug Congress
2011/08/26
(Added)Notice for Acquisition of Beijing Continent Pharmaceutical Co. Ltd.
2011/08/24
Notice of Increasing the Capital of Shanghai Genomics
2011/08/02
GNI Receives Patent Allowance on F351 and F647
2011/07/13
Notice for Acquisition of Beijing Continent Pharmaceutical Co. Ltd.
2011/07/13
Notice for Dissolving Term Sheet to Acquire Hengshan Pharmaceuticals Co. Ltd.
2011/07/07
GNI Group Files IND for Drug on Liver Failure
2011/05/11
ChinaBio Partnering Forum 2011
2011/04/27
The 4th Industrial Biotechnology (ibio) Conference
  • <
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • >
画像

GNI

About Us
Message
Business Model
Main Products
Management Policy
Company Overview
Board of Directors
Main Group Structure
Office
Corporate Governance Policy
Investor Relations
IR News
IR Materials
IR Calendar
Electronic Public Notices
IR Email Subscription
R&D
Pipeline
Discovery Research
Research publications
Sustainability/ESG
Sustainability Initiatives
ESG Data
Contact Us
Career
Site Map
Privacy Policy
Terms of Use
Social Media Policy
Site Map
Privacy Policy
Terms of Use
Social Media Policy

© GNI Group Ltd. All Rights Reserved.